AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU (fam-trastuzumab deruxtecan-nxki) for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials, respectively.

Regulatory Milestone

Product Profile & Innovation

• Molecule: HER2-directed antibody drug conjugate (ADC) with DXd payload
• Technology: Specifically engineered with high drug-to-antibody ratio and membrane-permeable payload
• Development: Discovered by Daiichi Sankyo, jointly developed and commercialized globally by AstraZeneca and Daiichi Sankyo
• Therapeutic Expansion: First ADC to demonstrate efficacy in both neoadjuvant and adjuvant early breast cancer settings

Clinical Evidence – Dual Phase 3 Trial Success

DESTINY-Breast11 (Neoadjuvant Setting)

• Regimen: ENHERTU followed by THP (docetaxel, trastuzumab, pertuzumab)
• Primary Endpoint: Pathologic complete response (pCR) rate
• Results: 67.3% pCR with ENHERTU-based regimen vs. 56.3% with standard ddAC-THP
• Statistical Significance: Demonstrated superior pCR rates with clinically meaningful improvement

DESTINY-Breast05 (Adjuvant Setting)

• Population: Patients with residual invasive disease following neoadjuvant therapy
• Comparator: Trastuzumab emtansine (T-DM1)
• Primary Endpoint: Invasive disease-free survival (IDFS)
• Results: 53% reduction in risk of invasive disease recurrence or death (HR 0.47)
• Safety: No new safety concerns identified; consistent with established ENHERTU profile

Market Context & Competitive Landscape

HER2-positive breast cancer represents approximately 15-20% of all breast cancer cases, with early-stage disease affecting over 50,000 patients annually in the US. Current standard of care includes:

• Neoadjuvant: Anthracycline/taxane-based regimens with dual HER2 blockade
• Adjuvant: T-DM1 for patients with residual disease post-neoadjuvant therapy

ENHERTU’s competitive advantages:

• Dual setting approval provides comprehensive treatment continuum from neoadjuvant through adjuvant
• Superior pCR rates in neoadjuvant setting may translate to improved long-term outcomes
• Significant IDFS benefit in adjuvant setting establishes new standard of care for high-risk patients
• Established safety profile from extensive metastatic breast cancer experience

Commercial Implications

• Revenue Impact: Expected to significantly expand ENHERTU’s addressable market beyond metastatic setting
• Pricing Strategy: Premium pricing maintained across both new indications reflecting clinical superiority
• Market Penetration: Rapid adoption anticipated given strong clinical data and established physician familiarity
• Competitive Disruption: Likely to displace T-DM1 as adjuvant standard and challenge anthracycline-based neoadjuvant regimens

Strategic Significance

• ADC Leadership: Reinforces AstraZeneca and Daiichi Sankyo’s position as leaders in next-generation antibody drug conjugate development
• Treatment Paradigm Shift: Establishes ENHERTU as backbone therapy across the entire HER2-positive breast cancer continuum
• Global Harmonization: US approval supports ongoing regulatory submissions in other major markets
• Platform Validation: Success validates DXd ADC platform for early-stage disease applications beyond metastatic settings

Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial performance for ENHERTU. Actual results may differ due to risks including market adoption rates, competitive dynamics, and reimbursement decisions.-Fineline Info & Tech